DDAH1 and triple-negative breast carcinoma: DDAH1 activity was inhibited in triple negative breast cancer cell lines by the potent DDAH1 inhibitors, arginine analogs ZST316 and ZST152 (244, 249), as identified by increased intracellular ADMA concentrations and decreased intracellular L-citrulline concentrations (55).